RelēF Technology consists of monopolar capacitive-coupled Radiofrequency (mcRF) and reverse thermal gradient. While protecting the superficial layers with cooling, RelēF Technology generates electric and thermal fields in deep tissues that progressively may result in initiation of the wound healing response, deactivation of small afferent or nociceptor nerve fibers (neuromodulation) and breakdown of nerve tissue (neurolysis) via non-invasive electrocoagulation.

RelēF Technology represents a technological advancement that is revolutionizing the therapeutic approach to common pathologies such as tennis elbow, golfer’s elbow, Achilles tendinosis, residual and functional joint instability, and enthesopathies in general.

Use of the RelēF Technology

Safe Procedure: A complete procedure can be performed in a time-efficient manner.

Non-invasive: The procedure is totally non-invasive. There are no surgery-related complications such as possible infection, recovery time or time off work.

Benefits: Protocol-led studies report success rates in excess of 80% based on VAS (Visual Analog Scale) scores and a high level of patient satisfaction. Plus, more than 700,000 patients have been treated with this monopolar capacitive-coupled Radiofrequency (mcRF) technology for non-orthopaedic applications with an excellent safety profile.

Easy to Use: RelēF Technology consists of a RF generator, a handpiece and treatment electrodes. The treatment is straightforward to administer.

No Anesthetic Needed: Patients who have been treated with RelēF Technology for different conditions have found the procedure very tolerable.

Contraindications: The AT2 and AT3 Systems featuring RelēF Technology are contraindicated for use in patients with either an implantable pacemaker, an Automatic Implantable Cardioverter/Defibrillator (AICD) or any other implantable electrical device as these devices may be adversely affected by radiofrequency (RF) field or current.